Increase in Both CD14-Positive and CD15-Positive Myeloid-Derived Suppressor Cell Subpopulations in the Blood of Patients with Glioma but Predominance of CD15-Positive Myeloid-Derived Suppressor Cells in Glioma Tissue

Journal of Neuropathology and Experimental Neurology

Volumn 74, Issue 5, 2015, Pages 390-400

  Gielen, Paul R ^a   Schulte, Barbara M ^a   Kers Rebel, Esther D ^a   Verrijp, Kiek ^b   Petersen Baltussen, Harriëtte M J M ^b   Ter Laan, Mark ^b   Wesseling, Pieter ^b,c   Adema, Gosse J ^a  

^a RADBOUD UNIVERSITY MEDICAL CENTER   (Netherlands)

^b RADBOUD UNIVERSITY MEDICAL CENTER   (Netherlands)

^c VU UNIVERSITY MEDICAL CENTER   (Netherlands)

Author keywords

Blood; Glioblastoma; Myeloid derived suppressor cells; Tumor microenvironment

Indexed keywords

B7 ANTIGEN; CD14 ANTIGEN; CD15 ANTIGEN; HLA ANTIGEN CLASS 2; LEUKOCYTE ANTIGEN;

ARTICLE; BONE MARROW CELL; CELL SUSPENSION; CONTROLLED STUDY; GLIOBLASTOMA; HUMAN; HUMAN CELL; IMMUNOHISTOCHEMISTRY; MAJOR HISTOCOMPATIBILITY COMPLEX; PERIPHERAL BLOOD MONONUCLEAR CELL; PHENOTYPE; PRIORITY JOURNAL; PROTEIN EXPRESSION; SIGNAL TRANSDUCTION; SUPPRESSOR CELL; T LYMPHOCYTE SUBPOPULATION; TUMOR MICROENVIRONMENT; ADULT; AGED; BLOOD; BRAIN TUMOR; FEMALE; FLOW CYTOMETRY; GLIOMA; MALE; METABOLISM; MIDDLE AGED; PATHOLOGY; REGULATORY T LYMPHOCYTE; YOUNG ADULT;

ADULT; AGED; ANTIGENS, CD; ANTIGENS, CD14; ANTIGENS, CD15; BRAIN NEOPLASMS; FEMALE; FLOW CYTOMETRY; GLIOMA; HISTOCOMPATIBILITY ANTIGENS CLASS II; HUMANS; MALE; MIDDLE AGED; MYELOID CELLS; T-LYMPHOCYTES, REGULATORY; YOUNG ADULT;

EID: 84931042625     PISSN: 00223069     EISSN: 15546578     Source Type: Journal    
DOI: 10.1097/NEN.0000000000000183     Document Type: Article

References (41)

1. Louis DN, Ohgaki H, Wiestler OD, et al. WHO Classification of Tumours of the Central Nervous System. Lyon, France: International Agency for Research on Cancer, 2007
2. Gousias K, Markou M, Arzoglou V, et al. Frequent abnormalities of the immune system in gliomas and correlation with the WHO grading system of malignancy. J Neuroimmunol 2010;226:136-42
3. Carson MJ, Doose JM, Melchior B, Schmid CD, Ploix CC. CNS immune privilege: Hiding in plain sight. Immunol Rev 2006;213:48-65
4. Gielen P, van der Valk P, Wesseling P. Immune responses to tumours in the CNS. In: Woodroofe N, Amor S, eds. Neuroinflammation and CNS Disorders. Chichester, UK: John Wiley & Sons Ltd, 2014:363-84
5. Couzin-Frankel J. Breakthrough of the year 2013. Cancer immunotherapy. Science 2013:342;1432-33
6. Marsh JC, Goldfarb J, Shafman TD, Diaz AZ. Current status of immunotherapy and gene therapy for high-grade gliomas. Cancer Control 2013;20:43-48
7. Grauer OM, Wesseling P, Adema GJ. Immunotherapy of diffuse gliomas: Biological background, current status and future developments. Brain Pathol 2009;19:674-93
8. Lindau D, Gielen P, Kroesen M, Wesseling P, Adema GJ. The immunosuppressive tumour network: Myeloid-derived suppressor cells, regulatory T cells and natural killer T cells. Immunology 2013;138:105-15
9. Hanahan D, Weinberg RA. Hallmarks of cancer: The next generation. Cell 2011;144:646-74
10. Finocchiaro G, Pellegatta S. Immunotherapy for glioma: Getting closer to the clinical arena Curr Opin Neurol 2011;24:641-47
11. Jacobs JF, Idema AJ, Bol KF, et al. Regulatory T cells and the PD-L1/PD-1 pathway mediate immune suppression in malignant human brain tumors. Neuro Oncol 2009;11:394-402
12. Jacobs JF, Idema AJ, Bol KF, et al. Prognostic significance and mechanism of Treg infiltration in human brain tumors. J Neuroimmunol 2010; 225:195-99
13. Fecci PE, Mitchell DA, Whitesides JF, et al. Increased regulatory T-cell fraction amidst a diminished CD4 compartment explains cellular immune defects in patients with malignant glioma. Cancer Res 2006;66:3294-302
14. Heimberger AB, Abou-Ghazal M, Reina-Ortiz C, et al. Incidence and prognostic impact of FoxP3+ regulatory T cells in human gliomas. Clin Cancer Res 2008;14:5166-72
15. Gabitass RF, Annels NE, Stocken DD, Pandha HA, Middleton GW. Elevated myeloid-derived suppressor cells in pancreatic, esophageal and gastric cancer are an independent prognostic factor and are associated with significant elevation of the Th2 cytokine interleukin-13. Cancer Immunol Immunother 2011;60:1419-30
16. Diaz-Montero CM, Salem ML, Nishimura MI, Garrett-Mayer E, Cole DJ, Montero AJ. Increased circulating myeloid-derived suppressor cells correlate with clinical cancer stage, metastatic tumor burden, and doxorubicincyclophosphamide chemotherapy. Cancer Immunol Immunother 2009;58: 49-59
17. Youn JI,Nagaraj S, CollazoM,GabrilovichDI. Subsets of myeloid-derived suppressor cells in tumor-bearing mice. J Immunol 2008;181:5791-802
18. Movahedi K, Guilliams M, Van den Bossche J, et al. Identification of discrete tumor-induced myeloid-derived suppressor cell subpopulations with distinct T cellYsuppressive activity. Blood 2008;111:4233-44
19. Solito S, Marigo I, Pinton L, Damuzzo V, Mandruzzato S, Bronte V. Myeloid-derived suppressor cell heterogeneity in human cancers. Ann N Y Acad Sci 2014;1319:47-65
20. Yang R, Cai Z, Zhang Y, Yutzy WH4th, Roby KF, Roden RB. CD80 in immune suppression by mouse ovarian carcinoma-associated Gr-1+CD11b+ myeloid cells. Cancer Res 2006;66:6807-15
21. Pan PY, Ma G, Weber KJ, et al. Immune stimulatory receptor CD40 is required for T-cell suppression and T regulatory cell activation mediated by myeloid-derived suppressor cells in cancer. Cancer Res 2010;70:99-108
22. Poschke I, Mougiakakos D, Hansson J, Masucci GV, Kiessling R. Immature immunosuppressive CD14+HLA-DRj/low cells in melanoma patients are Stat3hi and overexpress CD80, CD83, and DC-Sign. Cancer Res 2010;70:4335-45
23. Zhang B, Wang Z, Wu L, et al. Circulating and tumor-infiltrating myeloid-derived suppressor cells in patients with colorectal carcinoma. PLoS One 2013;8:e57114
24. Mandruzzato S, Solito S, Falisi E, et al. IL4Ralpha+ myeloid-derived suppressor cell expansion in cancer patients. J Immunol 2009;182:6562-68
25. Quaranta V, Walker LE, Pellegrino MA, et al. Purification of immunologically functional subsets of human IaYlike antigens on a monoclonal antibody (Q5/13) immunoadsorbent. J Immunol 1980;125:1421-25
26. Sippel TR, White J, Nag K, et al. Neutrophil degranulation and immunosuppression in patients with GBM: Restoration of cellular immune function by targeting arginase I. Clin Cancer Res 2011;17:6992-7002
27. Jang TJ, Park JB, Lee JI. The expression of CD10 and CD15 is progressively increased during colorectal cancer development. Korean J Pathol 2013;47:340-47
28. Walter S, Weinschenk T, Stenzl A, et al. Multipeptide immune response to cancer vaccine IMA901 after single-dose cyclophosphamide associates with longer patient survival. Nat Med 2012;18:1254-61
29. Filipazzi P, Valenti R, Huber V, et al. Identification of a new subset of myeloid suppressor cells in peripheral blood of melanoma patients with modulation by a granulocyte-macrophage colony-stimulation factorYbased antitumor vaccine. J Clin Oncol 2007;25:2546-53
30. Hoechst B, Ormandy LA, Ballmaier M, et al. A new population of myeloid-derived suppressor cells in hepatocellular carcinoma patients induces CD4(+)CD25(+)Foxp3(+) T cells. Gastroenterology 2008;135: 234-43
31. Raychaudhuri B, Rayman P, Ireland J, et al. Myeloid-derived suppressor cell accumulation and function in patients with newly diagnosed glioblastoma. Neuro Oncol 2011;13:591-99
32. Kohanbash G, McKaveney K, Sakaki M, et al. GM-CSF promotes the immunosuppressive activity of glioma-infiltrating myeloid cells through interleukin-4 receptor->. Cancer Res 2013;73:6413-23
33. Gustafson MP, Lin Y, New KC, et al. Systemic immune suppression in glioblastoma: The interplay between CD14+HLA-DRlo/neg monocytes, tumor factors, and dexamethasone. Neuro Oncol 2010;12:631-44
34. Brandau S, Moses K, Lang S. The kinship of neutrophils and granulocytic myeloid-derived suppressor cells in cancer: Cousins, siblings or twins Semin Cancer Biol 2013;23:171-82
35. Duffy A, Zhao F, Haile L, et al. Comparative analysis of monocytic and granulocytic myeloid-derived suppressor cell subsets in patients with gastrointestinal malignancies. Cancer Immunol Immunother 2013;62: 299-307
36. Kotsakis A, Harasymczuk M, Schilling B, Georgoulias V, Argiris A, Whiteside TL. Myeloid-derived suppressor cell measurements in fresh and cryopreserved blood samples. J Immunol Methods 2012;381:14-22
37. Dietrich J, Rao K, Pastorino S, Kesari S. Corticosteroids in brain cancer patients: Benefits and pitfalls. Expert Rev Clin Pharmacol 2011;4:233-42
38. Moon EY, Ryu YK, Lee GH. Dexamethasone inhibits in vivo tumor growth by the alteration of bone marrow CD11b+ myeloid cells. Int Immunopharmacol 2014;21:494-500
39. Varga G, Ehrchen J, Tsianakas A, et al. Glucocorticoids induce an activated, anti-inflammatory monocyte subset in mice that resembles myeloid-derived suppressor cells. J Leukoc Biol 2008;84:644-50
40. Raychaudhuri B, Rayman P, Huang P, et al. Myeloid-derived suppressor cell infiltration of murine and human gliomas is associated with reduction of tumor infiltrating lymphocytes. J Neurooncol 2015. [Epub ahead of print]
41. Prosniak M, Harshyne LA, Andrews DW, et al. Glioma grade is associated with the accumulation and activity of cells bearing M2 monocyte markers. Clin Cancer Res 2013;19:3776-86